Evaluation of elevated alanine aminotransferase and hepatitis B virus DNA in healthy seronegative blood donors

BMC Research Notes

Tariq Moatter¹  Bushra Moiz¹  Natasha Ali¹ 

[1] Department of Pathology and Microbiology, The Aga Khan University Hospital, P.O Box 3500, Stadium Road, Karachi, 74800, Pakistan

关键词: Blood donors;    Hepatitis B;    ALT;   

Others  :  1166362
DOI  :  10.1186/1756-0500-5-272

 received in 2012-02-02, accepted in 2012-05-24,  发布年份 2012

【 摘 要 】

Background

Serum alanine transaminase (ALT) has been used as a surrogate marker for detection of hepatitis B and C in blood donors in Pakistan since 1985. Since the introduction of more sensitive assays the value of ALT became questionable but it was still used with subsequent wastage of blood units with raised ALT.

Findings

We conducted a study for a period of one year to evaluate the usefulness of ALT. During the study period, 25117 subjects donated blood. Eight hundred and seventy two donors (3.4%) were positive for one or more serological tests. ALT of all donors ranged from 0–1501 U/L (Mean ± SD; 33.4 ± 25.45U/L). The donors seronegative for all disease markers were 24245 (96.6%). Of these, 21164 (84.2%) donors had their ALT within reference range while 2874 (11.4%) and 207 (0.8%) of donors had minimal and markedly elevated results respectively. Six hundred and twenty one blood units (including red cells, platelets and plasma) were discarded based on elevated ALT results alone at a cost of $39,123. Two hundred seronegative blood donors with normal ALT, minimally and markedly elevated ALT levels, were selected randomly and evaluated for hepatitis B deoxynucleic acid by individual PCR. None of the donors was found to be reactive.

Conclusion

This work did not support a positive association between hepatitis B virus nucleic acid and elevated ALT in healthy serologically negative blood donors.

【 授权许可】

   
2012 Ali et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Proceedings of the European Association for the Study of the Liver (EASL) International Consensus Conference on Hepatitis B. September 14–16, 2002. Geneva, Switzerland J Hepatol 2003, 39(Suppl 1):S1-S235.
• [2]Jamali R, Khonsari M, Merat S, Khoshnia M, Jafari E, Bahram Kalhori A, Abolghasemi H, Amini S, Maghsoudlu M, Deyhim MR, et al.: Persistent alanine aminotransferase elevation among the general Iranian population: prevalence and causes. World J Gastroenterol 2008, 14(18):2867-2871.
• [3]Goncales Junior FL, Stucchi RS, Papaiordanou PM, Pavan MH, Goncales NS, Pinho JR: Elevated alanine aminotransferase (ALT) in blood donors: an assessment of the main associated conditions and its relationship to the development of hepatitis C. Rev Inst Med Trop Sao Paulo 1998, 40(4):219-224.
• [4]Minekawa T, Ohkuma H, Abe K, Maekawa H, Arakawa H: Development of ultra-high sensitivity bioluminescent enzyme immunoassay for hepatitis B virus surface antigen using firefly luciferase. Luminescence 2009, 24(6):394-399.
• [5]Cable R, Badon S, Pray C, Popovsky MA: Limited utility of alanine aminotransferase screening of hepatitis C antibody-screened blood donors. Transfusion 1997, 37(2):206-210.